In vitro synthesis of IgE by human lymphocytes. IV. Suppression of the spontaneous IgE synthesis by IgE-binding factors secreted by tunicamycin-treated RPMI 8866 cells.

It was previously shown that RPMI 8866 cells released IgE-binding factors (IgE-BFs) capable of enhancing the spontaneous in vitro synthesis of IgE by purified B lymphocytes isolated from allergic individuals. In the present study, the influence of tunicamycin, an inhibitor of protein glycosylation, on RPMI 8866 cells was investigated with regard to: (i) the expression of surface receptors for IgE; (ii) the release of IgE-BFs into the culture supernatants, and (iii) the biological activity of IgE-BFs. After preincubation for 60 min with tunicamycin (1 microgram/ml), RPMI 8866 cells were cultured for 48 hr in HB 101 serum-free medium; the culture supernatant was then filtered, concentrated, and its biological activity was compared to that of a parallel culture supernatant from untreated RPMI 8866 cells. The results of these experiments indicate that exposure of RPMI 8866 cells to tunicamycin resulted in: (i) a reduction of surface Fc epsilon R; (ii) no effect on the release of IgE-BFs into the culture supernatant, and (iii) the conversion of IgE-potentiating factors into IgE-suppressing factors. The latter factors suppressed the IgE secretion by U266 myeloma cells and completely inhibited the activity of IgE-potentiating factors on B lymphocytes from allergic individuals. IgE-BFs secreted by tunicamycin-treated cells had no effect on the production of IgG, IgA or IgM by normal or EBV-transformed B cells.     

In vitro synthesis of IgE by human lymphocytes. III. IgE-potentiating activity of culture supernatants from Epstein-Barr virus (EBV) transformed B cells.

Seven Epstein--Barr virus (EBV)-transformed B cell lines were derived from circulating lymphocytes of two atopic and two non-atopic individuals, two preparations of cord blood lymphocytes and one tonsillar lymphocyte preparation. All the cell lines contained a significant proportion of cells expressing Fc epsilon R as detected by rosette formation with IgE-coated bovine erythrocytes (E-IgE) and by flow cytometry using IgE-linked to fluorescent microspheres. None of the cell lines displayed FcR for IgA, IgM or IgG. The cell-free supernatants (CFS) of EBV-transformed cells contained IgE-binding factors (IgE-BFs) detected by their ability to inhibit the binding to RPMI 8866 cells of either E-IgE or IgE-linked to microspheres. Whereas these CFS enhanced the synthesis of IgE and suppressed the synthesis of IgG by purified B lymphocytes isolated from the blood of allergic donors and cultured in the absence of stimulant, their effect on the synthesis of IgA or IgM was not predictable. CFS significantly enhanced the secretion of IgE by the U266 myeloma cell line without interfering with secretion of IgM, IgG or IgA by EBV-transformed cells. These data are in accord with similar properties of RPMI 8866 cells and suggest that B lymphocytes might play a regulating role in the IgE synthesis.     

Enhancement of IgE synthesis and histamine release by T cell factors derived from atopic patients with bronchial asthma

Culture supernatants of unstimulated T cells (TCS) derived from normal donors or from atopic patients with bronchial asthma were tested for their ability to regulate the spontaneous IgE synthesis by B cells of normal and atopic subjects. The same TCS were also tested for their influence on the histamine release from leukocytes of house dust mites-sensitive patients. Addition of TCS to B cell cultures from allergic donors induced a dose-dependent increase of the spontaneous IgE production without affecting the synthesis of IgG, IgM, and IgA. The potentiating activity of TCS was observed only in B cell cultures spontaneously producing IgE; TCS were still active on irradiated B cells. The maximal IgE-enhancing activity was observed when TCS were added at the onset of B cell cultures. The supernatants of T cells lysed at day 0 did not contain IgE-potentiating factors. The antigen-induced but not the spontaneous histamine release from leukocytes of house dust mite-sensitive patients was enhanced by pretreatment with TCS from allergic donors. The enhancing activities of TCS on IgE synthesis and on histamine release could be removed by absorption with IgE-Sepharose and subsequently recovered by elution with glycine buffer. The results indicate that T cells of patients with asthma spontaneously release IgE-binding factors capable of increasing both the spontaneous IgE synthesis by B cells and the antigen-induced histamine release.     

In vitro synthesis of IgE by human lymphocytes. I. The spontaneous secretion of IgE by B lymphocytes from allergic individuals: a model to investigate the regulation of human IgE synthesis

In view of the controversial data in the literature regarding the in vitro IgE synthesis by human lymphocytes, the conditions for culture of lymphocytes and the methodology for measurement of the IgE produced are described in detail. In the absence of any added mitogen, enriched B cell preparations derived from 70% of allergic donors actively secreted 100 to 3200 pg/ml of IgE after culture for 7 days, at which time the cell viability was higher than 85%. In comparable B cell cultures derived from non-allergic donors, only trace amounts of de novo synthesized IgE were detected in 20% of the cases. All B cell cultures actively secreted IgG, IgA, IgM and there was no apparent relationship between the secretion of IgE and that of the other classes of Ig. By contrast, the synthesis of IgE by unfractionated peripheral blood mononuclear cells of allergic individuals, which were stimulated with pokeweed mitogen (PWM) under several experimental conditions, was not consistently reproducible, i.e. the spontaneous synthesis of IgE in such cultures was either suppressed or enhanced by PWM. The most important finding was that the secretion of IgE was selectively enhanced by supplementing the B cell cultures with cell-free supernatants (CFS) of cultures of neonatal lymphocytes which had been preincubated with 10 micrograms/ml IgE. It is, therefore, concluded that B cell cultures from allergic individuals constitute an appropriate model for investigations of the mechanisms underlying the regulation of human IgE synthesis.     

Regulation of ongoing IgE synthesis by human T-cell supernatants derived from atopic and nonatopic donors

Supernatants derived from T cells of donors with and without atopic disease were assessed to determine whether they could regulate ongoing IgE, IgG, or IgA synthesis of three different human B-cell lines. The results were compared with the ability of T-cell supernatants from the atopic donors to specifically induce IgE synthesis of nonatopic peripheral blood B lymphocytes (PBL-B cells). We found that, when tested on the B-cell lines, the T-cell supernatants from atopic donors doubled the IgE as well as the IgG and IgA synthesis. Although the T-cell supernatants from nonatopic donors had no effect on Ig synthesis of PBL-B cells or on the IgG of the IgG-secreting cell line, the supernatants doubled the IgE and moderately enhanced IgA synthesis of the IgE- and IgG-secreting cell lines. These results demonstrate that T-cell supernatants derived from atopic and nonatopic donors differ in their regulatory effects, not only on PBL-B cells, as had been shown previously by others, but also in their effects on ongoing Ig production.     

Characterization of human T cell-derived IgE-potentiating factor

We have previously shown that Fc epsilon receptor-positive (Fc epsilon R+) T cell lines from patients with the hyper IgE syndrome secrete IgE-binding factors which selectively enhance IgE but not IgG synthesis in cultures of B cells obtained from patients with allergic rhinitis but not from nonatopic subject. In the present study we have tested the effect of supernatants from Fc epsilon R+ T cell lines on a large panel of B cells from atopic patients (n = 20). We found that IgE synthesis was selectively enhanced only in B cell cultures in which there was ongoing spontaneous synthesis of IgE. The target of IgE-potentiating factor(s) was a large low-density B cell present in the circulation of responding atopic donors. In addition, we further characterized IgE-potentiating factors derived from Fc epsilon R+ T cell lines. The factor(s) fractionated into 2 peaks on Sephadex G-75 with approximate molecular masses of 15,000 and 60,000 kDa, and had affinity for lentil lectin but not for peanut agglutinin. Release of IgE-potentiating factor(s) was enhanced by the addition of exogenous human IgE to Fc epsilon R+ T cell cultures and was inhibited by tunicamycin, an inhibitor of N-glycosylation. These studies suggest a close homology between the physicochemical characteristics of human and rodent IgE-potentiating factors and the immune signals which modulate production of these IgE regulatory factors.     

IgE synthesis in vitro induced by T cell factors from patients with elevated serum IgE levels

The effect of unstimulated T cell culture supernatants (TCS) from patients with atopic dermatitis and high serum IgE levels on the IgE production in vitro by B cell rich suspensions from normal individuals or grass pollen sensitive patients with mild atopy was evaluated. TCS from patients with raised IgE enabled B cell suspensions from normal individuals to produce detectable amounts of IgE and potentiated the spontaneous IgE synthesis in vitro by B cell suspensions from grass sensitive patients. In contrast, the addition of TCS from normal subjects with low serum IgE levels did not increase or even reduced IgE synthesis by B cell cultures. When the same B cell cultures were analysed for their ability to produce IgG or IgM protein, no significant differences were observed. These findings indicate that T lymphocytes from patients with high serum IgE levels can release soluble factor(s) possessing isotype (IgE) specific potentiating activity.     

A flow cytometric micromethod for the detection of Fc epsilon receptors and IgE binding factors using fluorescent microspheres

Two assays based on the use of fluorescent microspheres have been developed in order to detect Fc epsilon receptors on human cells and human IgE binding factors. A direct assay using microspheres to which IgE was coupled permitted the detection of Fc epsilon receptors on RPMI 8866 cells. However the fluorescence intensity was relatively low and made it difficult to discriminate between positive and negative cells. To increase the sensitivity of the assay, an indirect 3-step test was developed, in which the cells were subsequently incubated with soluble IgE, a polyclonal or monoclonal anti-IgE antibody and fluorescent microspheres to which anti-mouse or anti-rabbit immunoglobulin was coupled. This indirect assay resulted in an increased fluorescence intensity. Optimal discrimination between positive and negative cells was obtained. This assay permitted the detection of human IgE binding factors produced by RPMI 8866 cells. The binding of IgE was not dependent on the origin of the latter. Among the different cell lines tested, the EBV positive lymphoblastoid cells were found to express Fc epsilon receptors and to release IgE binding factors in their supernatants.     

Antigen-induced inhibition of human in vitro spontaneous IgE synthesis. I. Factors and kinetic studies.

Peripheral blood mononuclear cells from patients with hypersensitivity to L. perenne and D. pteronyssinus were incubated with specific antigen. They were then cultured for 7 days in the absence of antigen and the IgE contained in the supernatants was determined using an enzyme immunoassay (ELISA). Pre-incubation of the cells with antigen produced an inhibitory effect on the spontaneous IgE synthesis in most of the cases (101 of the 134 individual studied). This inhibition was more pronounced and more frequent in those cultures with an elevated spontaneous production of IgE (3,000-10,000 pg/ml). This effect depended on the dose of antigen and the duration of cell exposure. Both spontaneous IgE production kinetics and antigen-mediated inhibition were studied. A study of the IgE content of the cell pellets indicated that the antigen did not induce inhibition of the IgE release. We therefore believe that the inhibition observed must be due to some kind of IgE synthesis suppression.     

Inhibition of human interleukin 4-induced IgE synthesis by a subset of anti-CD23/Fc epsilon RII monoclonal antibodies.

Specific monoclonal antibodies (mAb) directed against the CD23 antigen were used to study human interleukin 4 (hIL4)-induced IgE production by blood and tonsillar mononuclear cells. Both peripheral blood and tonsillar mononuclear cells stimulated by hIL4 expressed membrane CD23 as detected by the binding of all anti-CD23 mAb. Nevertheless, two sets of anti-CD23 mAb could be distinguished. The first set, including mAb 25, was able to decrease significantly hIL4-induced IgE synthesis by mononuclear cells. The second set, including EBVCS#1, did not affect hIL4-induced IgE synthesis. All the anti-CD23 mAb were able to bind specifically to a human B cell line expressing recombinant CD23. Inhibition experiments revealed that the two sets of anti-CD23 mAb did not recognize the same epitope on the CD23 antigen. In fact, all the anti-CD23 mAb, except EBVCS#1, were able to inhibit IgE binding to CD23 on RPMI 8866 cells. Moreover, the first set of antibodies, which decreased IgE production, was able to up-regulate membrane CD23 expression on hIL4-stimulated tonsillar mononuclear cells. Conversely, EBVCS#1, which had no effect on IgE production, did not affect hIL4-induced CD23 expression. These results indicate that CD23 plays a key role in human IgE synthesis.     

Presence of IgE suppressor factors in human colostrum

In spite of intensive investigations, the ability of breast feeding to delay and to attenuate atopic diseases in children remains debatable. This study documents a mechanism whereby breast feeding might interfere with the synthesis of IgE by breast-fed infants. Indeed, we show that colostrum contains IgE-binding factors (IgE-BF) capable of suppressing the in vitro synthesis of human IgE. Colostrum obtained from 15 donors was successively depleted of lipids and casein, filtered through Amicon XM50 membrane (mol. mass cut-off 50 kDa) and lyophilized. IgE-BF was demonstrated in such preparations by two different approaches, i.e. a classical rosette inhibition assay and Western blot analysis. In the first instance, lyophilized preparations of colostrum inhibited the binding of IgE-coated bovine erythrocytes to IgE recovered on the surface of RPMI 8866 lymphoblastoid cells. The rosette-inhibiting activity could be absorbed on IgE- but not on IgG-Sepharose 4B and it could be recovered in the eluate of IgE-Sepharose 4B. The molecular mass of IgE-BF was comprised between 10 to 20 kDa as estimated by gel filtration through a calibrated Sephadex G-75 column. After fractionation on 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transfer to nitrocellulose membrane, colostrum displayed one band of 14 kDa and reacted with radiolabeled IgE but not with IgG nor IgM. This 14-kDa band could be removed by absorbing colostrum with IgE- but not with IgG-Sepharose 4B. Most importantly, the colostrum IgE-BF suppressed the spontaneous in vitro synthesis of IgE by B lymphocytes derived from allergic donors without altering the production of IgM.     

IgE-binding factors. Selective regulation of the IgE response by T cell factors

Gene cloning of rodent IgE-binding factors was accomplished, using messenger RNA of a rat T cell hybridoma, 23B6, which produce IgE-suppressive factor. Transfection of cos 7 monkey kidney cells with a cDNA clone resulted in the formation of rodent IgE-potentiating factors. The results provided a definitive evidence that IgE-binding factors represent a single peptide chain, and that the IgE-potentiating factor and IgE-suppressive factor share a common structural gene. Nucleotide sequence of a cDNA provided predicted amino acid sequence of the 60K precursor molecules of IgE-potentiating factor. Human IgE-potentiating factors were obtained from a human T-T hybridoma. The factors have affinity not only for human IgE but also for rat IgE and selectively enhanced antigen-induced IgE response of rat lymphocytes. The same hybridoma could be switched to form IgE-suppressive factor by the addition of glycosylation-inhibiting factor (GIF) during its biosynthesis. Purified GIF has immunosuppressive activity in the mouse. This factor suppressed the primary IgE and IgG antibody responses in the mouse, and markedly suppressed ongoing IgE antibody formation.     

Effect of dexamethasone on de novo IgE synthesis by human blood lymphocytes

The effect of dexamethasone (DM) on de novo in vitro total IgE synthesis by blood mononuclear cells (MNC) was studied in atopic patients with eczema and in nonatopic control subjects. Unfractionated blood MNC were cultured at 1 X 10(6) cells per milliliter for 7 days in RPMI 1640 with 10% fetal calf serum with or without decreasing concentrations of DM (10(-7) to 10(-11). Net IgE synthesis was calculated by subtracting preformed (+ cycloheximide at day 0) from total IgE in 7-day supernatants. Supernatant IgE was measured by use of a modified PRIST assay. A significant increase in net IgE synthesis occurred in the presence of DM in 11 of 11 atopic patients with eczema (mean percent increase = 68%; p less than 0.05) and five of five atopic patients without eczema (mean percent increase = 53%; p 0.05) but not in seven of seven nonatopic controls. This increase in de novo IgE synthesis could not be explained by a significant change in cell viability. In five of five experiments, a mean increase of 78% was still noted when DM was added to atopic blood MNCs depleted of T cells by sheep red blood cell rosetting. The addition of 10(-9)M of DM to eczema B+ T cell recombinations enriched for suppressor cells (depleted of Leu 3a+ helper T cells) resulted in a loss of suppressor-T cell activity and maximal augmentation of IgE synthesis. Enhancement of IgE synthesis was also noted when DM was added to eczema B+ T cell recombinations enriched for helper T cells (depleted of suppressor Leu 2a+ T cells).(ABSTRACT TRUNCATED AT 250 WORDS)     

In vitro production of IgE by human peripheral blood mononuclear cells. I. Rate of IgE biosynthesis

IgE protein and grass-specific IgE antibodies were detected in the supernatants of 7-day cultures of unstimulated and pokeweed mitogen (PWM) stimulated human blood mononuclear cells from non-atopic and grass pollen-sensitive individuals. Significant amounts of IgE protein were detected in culture supernatants of grass-sensitive individuals and, even at lower levels, in those of non-atopic subjects. In contrast, detectable amounts of grass-specific antibodies were found only in the culture supernatants of grass-sensitive subjects. The mean values of total and grass-specific IgE detected in the supernatants of unstimulated and PWM-stimulated cultures did not differ statistically. Time sequence studies showed that IgE concentrations, measured in the 7-day supernatants, were due to a continuous release from the cells of IgE quantities progressively decreasing up to days 7 or 8. Comparison of the IgE protein and IgE antibody found in the 7-day culture supernatants to those released from initial cell pellets by treatment with acid buffer or freezing and thawing, showed that the IgE detected in 7-day supernatants could result, in part, from the release of cytophilic IgE bound to basophil or other cell types and in part also from the release of preformed lymphocyte cytoplasmic IgE into the supernatant fluids during the course of culture. In most non-atopic subjects and in some grass-sensitive patients the preformed IgE accounted virtually for the total IgE detected in the 7-day culture supernatants. However, the increase of IgE above the levels measured in the initial cell pellets, which was found in most grass-sensitive subjects, clearly reflected newly synthesized IgE. Both cycloheximide and puromycin were capable of reducing significantly the IgE concentration in culture supernatants when it was greater than the amount found in the initial cell pellets. The treatment of cells with mitomycin C was also able to decrease significantly the amount of IgE released in the supernatant after day 3 of culture.     

IgE secretion is attenuated by an inhibitor of proteolytic processing of CD23 (FcεRII)

CD23, the low-affinity IgE receptor, is up-regulated on interleukin (IL)-4-stimulated B cells and monocytes, with a concomitant increase in the release of soluble fragments of CD23 (sCD23) into the medium by proteolytic processing of the surface-bound intact CD23. The effect of inhibition of the processing of CD23 on IgE production in human and mouse cells and in a mouse model in vivo was evaluated. CD23 processing to sCD23 from RPMI 8866 (a human Epstein-Barr virus-transformed B cell line) cell membranes was inhibited by a broad-spectrum matrix-metalloprotease inhibitor, batimastat, with an IC₅₀ of 0.15 μM. Batimastat also inhibited CD23 processing in whole RPMI 8866 cells as well as in IL-4-stimulated purified human monocytes with similar IC₅₀. Batimastat inhibited IgE production from IL-4/anti-CD40-stimulated human tonsil B cells as well as mouse splenic B cells in a manner consistent with inhibition of CD23 processing. Release of soluble fragments of CD23 in the cell supernatants of tonsil B cells was inhibited over the concentration range of 1–10 μM batimastat and intact cell surface CD23 was increased on mouse splenic B cells in the presence of these concentrations of batimastat. IgE production of IL-4-stimulated human peripheral blood mononuclear cells was also blocked by 1–10 μM batimastat, again with comparable inhibition of sCD23 release over the same concentration range. Finally, in a mouse model of IgE production, batimastat inhibited IgE production in response to ovalbumin challenge as determined by serum IgE levels. Taken together, the data support a role of CD23 in IgE production and point to CD23 processing to sCD23 as a therapeutically relevant control point in the regulation of IgE synthesis.     

Abnormal regulation of in vitro IgE synthesis by T cells obtained from patients with atopic dermatitis

The regulatory influence of atopic eczema and non-atopic T cells on spontaneous IgE synthesis by eczema B cells was examined. Eczema B cells were cocultured with either autologous or allogeneic T cells in RPMI 1640 with 10% fetal calf serum at 0.75 X 10(6) cells/ml (B/T = 0.5) and supernatant IgE was measured by a modified PRIST assay. Net IgE synthesis was obtained by subtracting preformed IgE (+ cycloheximide at Day 0) from total IgE in 7-day supernatants. T cells were either untreated, heat-killed, exposed to 2000 rad, or depleted of helper/suppressor T cells by "panning" with monoclonal antibodies (Leu 3a and Leu 2a). Atopic eczema B cells spontaneously synthesized IgE when cultured alone. No significant suppression of net IgE synthesis occurred when atopic eczema T cells were cocultured with autologous B cells. In allogeneic recombinations, non-atopic T cells significantly suppressed net IgE synthesis by atopic eczema B cells (mean suppression = 59%; P less than 0.05). This suppression was abrogated if allogeneic control T cells were heat-killed, irradiated, or depleted of Leu 2a+ suppressor cells. In order to exclude an "allogeneic effect" as the sole mechanism to explain the suppression of IgE synthesis observed by coculturing non-atopic T cells with eczema B cells, the latter were recombined with either T cells from HLA-DR and mixed lymphocyte culture-matched sibling or autologous T cells. Greater suppression of net IgE synthesis was seen in the presence of histoidentical non-atopic T cells than in the presence of autologous eczema T cells, indicating that the latter have a partial defect in their suppressor function. This apparent "defect" in immunoregulatory function may be overcome by in vitro activation of atopic eczema T cells by concanavalin A.     

Regulatory effects of human IgE-binding factors in the IgE synthesis by human and rat lymphocytes

We have previously established human T cell hybridomas which produce IgE-binding factors. Incubation of one of the T cell hybridomas, 166A2, with human IgE dimer in the presence of 1 microgram/ml bradykinin resulted in the formation of IgE-binding factors having affinity for lentil lectin. The factors selectively enhanced both IgE-forming cell responses of rat mesenteric lymph node (MLN) cells and spontaneous IgE synthesis by human peripheral blood B cells of atopic patients, without affecting the IgG response. The same factors that enhanced IgE synthesis of B cells from atopic patients also enhanced IgE synthesis induced under bystander conditions by activated alloreactive T cells. Fractionation of the affinity-purified IgE-binding factors by gel filtration revealed three molecular mass species, i.e., 60 kDa, 30 kDa and 15 kDa. The 60-kDa and 15-kDa IgE-binding factors selectively enhanced both the spontaneous IgE synthesis by B cells of atopic patients and IgE response of rat MLN cells. In contrast, the 30-kDa IgE-binding factors had only marginal enhancing effects on the IgE synthesis by both human B cells and rat MLN cells. When the 166A2 hybridoma cells were incubated with IgE dimer in the presence of glycosylation-inhibiting factor (GIF), essentially all IgE-binding factors formed by the cells had affinity for peanut agglutinin (PNA) but for neither lentil lectin nor concanavalin A. All of the 60-kDa, 30-kDa and 15-kDa species, having affinity for PNA, selectively suppressed the potentiating factor-enhanced IgE response of rat MLN cells. The factors also suppressed the IgE synthesis of human B cells from atopic patients when the synthesis was enhanced by IgE-potentiating factor. The results indicate that human IgE-binding factors regulate IgE synthesis by both human and rat lymphocytes.     

鉴定IgE BF/sCD23的IgE介导的间接Western印迹技术的建立

基于 Western 印迹技术的基本原理,利用 IgE 结合因子/可溶性 CD23(IgEBF/sCD23)能够和 IgEFC 端特异性结合的特点,在系统研究了包括:IgE 浓度,反应时间及转移条件等数种因素后,首创了 IgE 介导的间接 Western 印迹技术.用于对 SDS—PAGE 电泳分离后样品中 IgEBF/sCD23特异性片段进行鉴定.实践证明:该法具有重复性高,操作简便及节约资金等优点.运用该技术,我们确定了 RPMI8866细胞上清中具有 IgEBF 活性的五种不同分子量的多肽.此方法的建立对开展 IgEBF/sCD23的研究以及其它特异性分子的鉴定都具有参考价值.     

Purification and partial biochemical characterization of IgE-binding factors secreted by a human B lymphoblastoid cell line.

IgE-binding factors (IgE-BFs) were purified from the culture supernatant of RPMI-8866 cells, a human lymphoblastoid B-cell line expressing IgE receptors. The material, purified by affinity-chromatography on immunoadsorbents coupled to IgE or to monoclonal antibody against IgE receptor, was comprised of two major components with apparent molecular weight (MW) of 25,000-27,000 and 12,000, as determined by SDS-PAGE and silver staining. Only the 25,000-27,000 MW molecules were identified as IgE-BFs, as demonstrated by their reactivity with MabER in the Western blot and the immunoprecipitation assays, and their ability to inhibit rosette formation of U937 cells with IgE- but not with IgG-coated erythrocytes. IgE-BFs were purified to homogeneity by combining affinity-chromatography and either DEAE-ion exchange or reverse-phase chromatography on an HPLC system. Chromatofocusing analysis demonstrated the microheterogeneity of IgE-BFs that were comprised of molecules with isoelectric points ranging from 5.0 to 4.4. IgE-BFs were sensitive to treatment with O-glycosidase but not with N-glycanase. These molecules were resistant to heat and to pH ranging from 2 to 9; their immunoreactivity was lost after treatment with trypsin and pepsin. Papain digestion of purified IgE-BFs generated 14,000-16,000 MW molecules that were still binding to IgE and to MabER.     

Affinity chromatography and SDS-PAGE studies of radiolabeled IgE-binding and IgG-binding factors generated from human lymphoblastoid cell lines

Soluble IgE-binding and IgG-binding factors were generated by 18-hour incubation at 4 degrees C of the human B cell lines RPMI 8866 and Daudi. These cells express Fc receptors for IgE (Fc epsilon R) and IgG (Fc gamma R), respectively. Binding factors specifically inhibited FcR on both lymphocytes and monocytes, and bound to Ig-Sepharose supports. RPMI 8866 cells and Daudi cells were radiolabeled with 125I by the lactoperoxidase method, and the soluble factors were labeled by the chloramine T method. Affinity chromatography of the soluble factors was performed with IgE-Sepharose, IgG-Sepharose and lentil-lectin-Sepharose followed by sodium dodecyl sulphate polyacrylamide gel electrophoresis and autoradiography. The finding of a common 22,000-dalton protein in supernatants with IgE binding, IgG binding, and non-binding activity is discussed in relation to methodological difficulties and the ambiguous results in the literature, as well as the possibility of a complex formation of macromolecules with binding factor activity.